# A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

> **NCT03134638** · PHASE1 · TERMINATED · sponsor: **Syros Pharmaceuticals** · enrollment: 107 (actual)

## Conditions studied

- Advanced Solid Tumors
- Ovarian Cancer
- Breast Cancer

## Interventions

- **DRUG:** SY-1365 (Part 1)
- **DRUG:** Carboplatin
- **DRUG:** Fulvestrant
- **DRUG:** SY-1365 (Cohort 2)
- **DRUG:** SY-1365 (Cohort 5)
- **DRUG:** SY-1365 (Part 2 Single Agent)

## Key facts

- **NCT ID:** NCT03134638
- **Lead sponsor:** Syros Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-12
- **Primary completion:** 2020-05-15
- **Final completion:** 2020-06-24
- **Target enrollment:** 107 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2021-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03134638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03134638, "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03134638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*